Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method
Treament | Trials | |||||
---|---|---|---|---|---|---|
clinical deterioration | clinical improvement | deaths | viral clearance | |||
2-deoxy-D-glucose (2-DG) | 0 | - | - | - | - | |
acetylcysteine | 0 | - | - | - | - | |
alpha lipoic acid | 0 | - | - | - | - | |
anti-CK2 | 0 | - | - | - | - | |
Aspirin | 0 | - | - | - | - | |
aviptadil | 0 | - | - | - | - | |
BLD-2660 (calpain inhibitor) | 0 | - | - | - | - | |
calcium channel blocker | 0 | - | - | - | - | |
camostat mesilate | 0 | - | - | - | - | |
Cannabidiol | 0 | - | - | - | - | |
continuous positive airway pressure (CPAP) | 0 | - | - | - | - | |
cytokine adsorption | 0 | - | - | - | - | |
diammonium glycyrrhizinate | 0 | - | - | - | - | |
dipyridamol | 0 | - | - | - | - | |
dornase alfa | 0 | - | - | - | - | |
expectorants and mucolytics | 0 | - | - | - | - | |
honey | 0 | - | - | - | - | |
kinin-kallikrein inhibitors | 0 | - | - | - | - | |
melatonin | 0 | - | - | - | - | |
mouthrise and gargling agents | 0 | - | - | - | - | |
N-Acetylcysteine | 0 | - | - | - | - | |
nasal spray | 0 | - | - | - | - | |
natural killer (NK) cells | 0 | - | - | - | - | |
nicotin | 0 | - | - | - | - | |
nigella sativa oil | 0 | - | - | - | - | |
nitric oxide (gas Inhalation or releasing solution) | 0 | - | - | - | - | |
omega-3 Polyunsaturated Fatty Acids | 0 | - | - | - | - | |
ozonated autohemotherapy | 0 | - | - | - | - | |
plasma exchange | 0 | - | - | - | - | |
povidone-iodine | 0 | - | - | - | - | |
previfenon (EGCG) | 0 | - | - | - | - | |
prostacyclin | 0 | - | - | - | - | |
PUL-042 inhalation solution | 0 | - | - | - | - | |
pyridostigmine | 0 | - | - | - | - | |
radiotherapy | 0 | - | - | - | - | |
sabizabulin | 0 | - | - | - | - | |
sildenafil | 0 | - | - | - | - | |
triiodothyronine (T3) | 0 | - | - | - | - |